Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin

American Journal of Medicine

Volumn 127, Issue 1, 2014, Pages 95.e1-95.e9

  Simpson, Scot H ^a   Abdelmoneim, Ahmed S ^a   Omran, Dima ^a   Featherstone, Travis R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Aspirin; Diabetes; Drug resistance; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DOSE RESPONSE; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; PLATELET REACTIVITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 84891590981     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.09.019     Document Type: Article

References (51)

1. Executive summary: standards of medical care in diabetes - 2013 Diabetes Care 36 Suppl 1 2013 S4 S10
2. J.A. Stone, D.H. Fitchett, S. Grover, R. Lewanczuk, and P. Lin Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada: vascular protection in people with diabetes Can J Diabetes 37 2013 S100 S104
3. M. Sacco, F. Pellegrini, M.C. Roncaglioni, F. Avanzini, G. Tognoni, A. Nicolucci, and PPP Collaborative Group Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial Diabetes Care 26 2003 3264 3272
4. J. Belch, A. MacCuish, and I. Campbell et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 2008 a1840
5. H. Ogawa, M. Nakayama, and T. Morimoto et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2008 2134 2141
6. L. Welin, L. Wilhelmsen, A. Björnberg, and A. Odén Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study Pharmacoepidemiol Drug Saf 18 2009 1143 1149
7. J. DiChiara, K.P. Bliden, and U.S. Tantry et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 56 2007 3014 3019
8. R. Fitzgerald, and M. Pirmohamed Aspirin resistance: effect of clinical, biochemical and genetic factors Pharmacol Ther 130 2011 213 225
9. O. Schnell, M. Erbach, and M. Hummel Primary and secondary prevention of cardiovascular disease in diabetes with aspirin Diab Vasc Dis Res 9 2012 245 255
10. G. Krasopoulos, S.J. Brister, W.S. Beattie, and M.R. Buchanan Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ 336 2008 195 198
11. J. Snoep, M. Hovens, J. Eikenboom, J. Van Der Bom, and M. Huisman Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis Arch Intern Med 167 2007 1593 1599
12. M.M. Hovens, J.D. Snoep, J.C. Eikenboom, J.G. van der Bom, B.J. Mertens, and M.V. Huisman Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review Am Heart J 153 2007 175 181
13. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
14. P.A. Gurbel, R.C. Becker, K.G. Mann, S.R. Steinhubl, and A.D. Michelson Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 2007 1822 1834
15. M.M. Hovens, J.D. Snoep, Y. Groeneveld, J.T. Tamsma, J.C. Eikenboom, and M.V. Huisman High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes J Thromb Haemost 5 2007 1562 1564
16. M. Rosiak, M. Postula, and A. Kaplon-Cieslicka et al. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study Kardiol Pol 71 2013 552 557
17. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White, and E.J. Topol A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 2003 961 965
18. L. Christiaens, S. Ragot, J. Mergy, J. Allal, and L. Macchi Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study Blood Coagul Fibrinolysis 19 2008 235 239
19. M.K. Singla, P. Lahiri, P. Mukhopadhyay, K. Pandit, U. Chaudhuri, and S. Chowdhury A study of aspirin resistance in type 2 diabetes J Indian Med Assoc 106 2008 720 723
20. A.B. Catakoglu, S. Aytekin, and H. Celebi et al. The influence of aspirin resistance on non-fatal coronary events following percutaneous coronary interventions Arch Med Sci 5 2009 531 538
21. P. Fontana, P. Berdague, and C. Castelli et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study J Thromb Haemost 8 2010 2614 2623
22. A. Feher, G. Pusch, and G. Harang et al. Aspirin resistance in cerebrovascular patients Int J Cardiol 152 2011 111 112
23. J. Cao, L. Liu, and L. Fan et al. The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease Aging Male 15 2012 140 147
24. I. Russo, C. Barale, and M. Chirio et al. A short-term improvement of blood glucose control increases aspirin sensitivity in aspirin-resistant type 2 diabetic men Diabetologia 55 2012 S102
25. D.C. Sane, S.A. McKee, A.I. Malinin, and V.L. Serebruany Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin Am J Cardiol 90 2002 893 895
26. L. Christiaens, L. Macchi, and D. Herpin et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease Thromb Res 108 2002 115 119
27. L. Macchi, E. Petit, A. Brizard, R. Gil, and J.P. Neau Aspirin resistance in vitro and hypertension in stroke patients J Thromb Haemost 2 2004 2051 2053
28. S. Fateh-Moghadam, U. Plockinger, and N. Cabeza et al. Prevalence of aspirin resistance in patients with type 2 diabetes Acta Diabetol 42 2005 99 103
29. P.A. Sadiq, A. Puri, and M. Dixit et al. Profile and prevalence of aspirin resistance in Indian patients with coronary artery disease Indian Heart J 57 2005 658 661
30. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention Am J Cardiol 97 2006 38 43
31. D. Bennett, B. Yan, L. Macgregor, D. Eccleston, and S.M. Davis A pilot study of resistance to aspirin in stroke patients J Clin Neurosci 15 2008 1204 1209
32. H.W. Cohen, J.P. Crandall, S.M. Hailpern, and H.H. Billett Aspirin resistance associated with HbA1c and obesity in diabetic patients J Diabetes Complications 22 2008 224 228
33. G. Feher, K. Koltai, G. Kesmarky, and K. Toth Hemorheological background of acetylsalicylic acid resistance Clin Hemorheol Microcirc 38 2008 143 152
34. H. Mardikar, D. Deo, and N. Deshpande et al. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population J Assoc Physicians India 56 2008 321 324
35. S. Prabhakaran, K.R. Wells, V.H. Lee, C.A. Flaherty, and D.K. Lopes Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting AJNR Am J Neuroradiol 29 2008 281 285
36. J.I. Seok, I.S. Joo, and J.H. Yoon et al. Can aspirin resistance be clinically predicted in stroke patients? Clin Neurol Neurosurg 110 2008 110 116
37. S. Acikel, A. Yildirir, and A. Aydinalp et al. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes Blood Coagul Fibrinolysis 20 2009 427 432
38. F.M. Pulcinelli, L.M. Biasucci, and S. Riondino et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment Eur Heart J 30 2009 1279 1286
39. M. Postula, B. Tarchalska-Krynska, and K.J. Filipiak et al. Factors responsible for "aspirin resistance" - can we identify them? Kardiol Pol 68 2010 403 411 discussion 412-413
40. A. Awidi, A. Saleh, and M. Dweik et al. Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study Heart Vessels 26 2011 516 522
41. L. Liu, J. Cao, and L. Fan et al. Prevalence and risk factors for aspirin resistance in elderly patients with type 2 diabetes Int J Gerontol 5 2011 112 116
42. P. Wientong, W. Jongjarornprasert, and D. Panomvana Platelet aggregation and serum thromboxane B2 level after taking 60 mg/day of aspirin in type 2 diabetic thai patients Int J Pharmacy Pharm Sci 3 2011 47 50
43. M.M. Salama, A.R. Morad, M.A. Saleh, N.A. Sabri, M.M. Zaki, and L.A. ElSafady Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors J Clin Pharm Ther 37 2012 630 636
44. T. Wcislo, M. Dominiak, and J. Kasprzak Hypertriglycerydemia - a predictor of platelet resistance to acetylsalicylic acid in patients with stable coronary artery disease Eur Heart J 33 2012 306
45. A. Abaci, Y. Yilmaz, and M. Caliskan et al. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes Thromb Res 116 2005 465 470
46. E.H. Law, and S.H. Simpson Aspirin use rates in diabetes: a systematic review and cross-sectional study Can J Diabetes 34 2010 211 217
47. G. De Berardis, M. Sacco, and V. Evangelista et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins Trials 8 2007 21
48. K.A. Schwartz, D.E. Schwartz, K. Ghosheh, M.J. Reeves, K. Barber, and A. DeFranco Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction Am J Cardiol 95 2005 973 975
49. J. Dawson, T. Quinn, and M. Rafferty et al. Aspirin resistance and compliance with therapy Cardiovasc Ther 29 2011 301 307
50. M. Friend, I. Vucenik, and M. Miller Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia BMJ 326 2003 82 83
51. V.L. Serebruany, S.R. Steinhubl, and P.B. Berger et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials Am J Cardiol 95 2005 1218 1222